➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Harvard Business School
McKesson
Baxter
Moodys
Boehringer Ingelheim

Last Updated: July 12, 2020

DrugPatentWatch Database Preview

RITUXAN HYCELA Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Recent Clinical Trials for RITUXAN HYCELA

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Genentech, Inc.Phase 2
Emory UniversityPhase 2
Acerta Pharma BVPhase 1

See all RITUXAN HYCELA clinical trials

Recent Litigation for RITUXAN HYCELA

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
CELGENE CORPORATION v. DR. REDDY'S LABORATORIES, LTD.2019-07-12
CELGENE CORPORATION v. APOTEX INC.2019-06-19
Genentech, Inc. v. Pfizer Inc.2019-04-05

See all RITUXAN HYCELA litigation

PTAB Litigation
PetitionerDate
Celltrion, Inc.2018-05-04
Apotex Inc.2018-02-23
2018-01-08

See all RITUXAN HYCELA litigation

Patent Text Search: US Patents for RITUXAN HYCELA

These patents were identified by searching patent claims

Supplementary Protection Certificates for RITUXAN HYCELA

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C300717 Netherlands   Start Trial PRODUCT NAME: POMALIDOMIDE EN FARMACEUTISCH AANVAARDBARE ZOUTEN, SOLVATEN, HYDRATEN OF STEREOISOMEREN DAARVAN; REGISTRATION NO/DATE: EU/1/13/850 20130805
122015000013 Germany   Start Trial PRODUCT NAME: POMALIDOMID UND SEINE PHARMAZEUTISCH AKZEPTABLEN SALZE, SOLVATE, HYDRATE ODER STEREOISOMERE (IMNOVID); REGISTRATION NO/DATE: EU/1/13/850 20130805
122016000093 Germany   Start Trial PRODUCT NAME: LBRUTINIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/14/945 20160526
CA 2017 00053 Denmark   Start Trial PRODUCT NAME: ANTISTOF-LAEGEMIDDEL-KONJUGAT, HVORI ET CD22-RETTET ANTISTOF ER BUNDET TIL N-ACETYL-GAMMA-CALICHEAMICIN, SVARENDE TIL INOTUZUMAB OZOGAMICIN; REG. NO/DATE: EU/1/17/1200 20170703
132017000036530 Italy   Start Trial PRODUCT NAME: IBRUTINIB O SUO SALE FARMACEUTICAMENTE ACCETTABILE(IMBRUVICA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/4/945, 20150707
132016000025345 Italy   Start Trial PRODUCT NAME: TRASTUZUMAB PER USO SOTTOCUTANEO(HERCEPTIN); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/00/145/002, 20130828
132017000135500 Italy   Start Trial PRODUCT NAME: SARILUMAB(KEVZARA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/17/1196, 20170627
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Medtronic
Boehringer Ingelheim
Baxter
Harvard Business School
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.